Facebook      Twitter

blank

blank

ONLINE LEARNING CENTER

HIV Treatment Guidelines & Cautions, and the Role of The Pharmacist in Care (12HC01)

 
 
 
CREDIT IS NO LONGER AVAILABLE FOR THIS ACTIVITY.
Content is provided for informational purposes only.

Release Date: June 2010
Expired: June 30, 2012
Activity Code: 12HC01-DE02
As seen in the June 2010 edition of

CREDIT IS NO LONGER AVAILABLE FOR THIS ACTIVITY. If you have any questions , please email the Center for Continuing and Outreach Education at ccoereg@ca.rutgers.edu or call CCOE Enrollment Services at (800) 227-4852.


ACTIVITY INFORMATION

Sponsor

Sponsored by the University of Medicine & Dentistry of New Jersey (UMDNJ), Center for Continuing & Outreach Education, Division of AIDS Education.

Funding

This activity is supported by an educational grant from the New Jersey Department of Health and Senior Services (NJDHSS) - Division of HIV/AIDS Services through a MOA titled “Education and Training for Physicians and other Healthcare Professionals in the Diagnosis and Treatment of HIV/AIDS. ”The New York/ New Jersey AETC (AIDS Education and Training Center (NY/NJAETC) provided in-kind support through the work of its Pharmacy Director, John Faragon, PharmD, BCPS, AAHIVE.

Target Audience

This application-based activity is designed for physicians, nurses, pharmacists, and other health care professionals in New Jersey who are involved in the care of persons with HIV/AIDS.

Statement of Need

The CDC and Infectious Disease Society of America (IDSA) issued updated antiretroviral treatment recommendations in December 2009,. Several agents have been reclassified as “not recommended” due to evidence of inferior virologic efficacy, high incidence of toxicities, and/or problems related to convenience.

The recommendations summarize findings of adverse effects and interactions between antiretroviral medications and other medical treatments.

Infectious disease clinicians may not have access to records allowing them to review all medications prescribed by other primary care and specialty care providers, to identify and avoid problematic combinations. Common treatments for tuberculosis, hyperlipidemia, seizure disorders, asthma, and many psychiatric illnesses have interactions with antiretroviral medications that may significantly increase or decrease concentration and risk under or overdosage. For example, iatrogenic Cushing's syndrome has been documented since 2002 in HIV-infected patients receiving ritonavir and inhaled fluticasone, but continues to be reported. HIV treatment should be planned to minimize interactions and adverse effects of combining HIV antiretroviral and other medications. The treatment team can include pharmacists, primary care providers, and specialists who also provide care to the same patient. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf

Learning Objectives

Upon completion of this activity, participants should be able to:

  1. List preferred, alternative/ acceptable and regimens not recommended that are included in the December 2009 revision on the Department of Health and Human Services (DHHS) Guidelines for HIV treatment.
  2. Provide examples of common medications used in the primary care setting that should be avoided in patients receiving HIV treatment.
  3. Describe the role of the pharmacist in HIV care.
  4. Reduce medication errors through use of guidelines and/or pharmacist consultation.

Faculty

John Faragon, PharmD, BCPS, AAHIVE is a pharmacist at Albany Medical Center in Albany, NY, and NY/NJAETC Regional Pharmacy Director.

Activity Director(s)/CME Academic Advisor(s)

Patricia Kloser, MD, MPH, Professor of Medicine, UMDNJ-New Jersey Medical School

Planning Committee

  • Sindy Paul, MD, MPH, FACPM, Medical Director, Division of HIV/AIDS Services, NJ Department. of Health and Senior Services
  • Debbie Y. Mohammed, MS, MPH, APRN-BC, ACRN, Nurse Practitioner, UMDNJ-University Hospital and St.Michael’s Medical Center – Peter Ho Clinic
  • Kimi Nakata, MSW, MPH, UMDNJ-CCOE-Division of AIDS Education Program
    Supervisor and NJ AIDSLine Editor
  • John Faragon, PharmD, BCPS, AAHIVE; NY/NJ AETC Clinical Pharmacy Director; Pharmacist, Albany Medical Center

Method of Instruction

Participants should read the learning objectives and review the activity in its entirety. Estimated time to complete this activity as designed is 1.25 hours for physicians and pharmacists, and 1.33 hours for nurses.

Accreditation

Credit is no longer available for this activity.

Review

This activity was peer reviewed for relevance, accuracy of content, and balance of presentation by Patricia Kloser, MD, MPH; Debbie Mohammed, MS, MPH, APRN-BC, AACRN; Humberto Jimenez, PharmD, AAHIVE, Clinical Assistant Professor, Ernest Mario School of Pharmacy, Rutgers University; and Brenda Christian, MEd, PA-C; Director of AIDS Education, UMDNJ-CCOE; and pilot tested for relevance and time required for participation by Kinshasa Morton, MD; Shobha Swaminathan, MD; Bonnie Abedini, MSN, RN; Mary C. Krug, MSN, APN; Kara Winslow, BSN, RN; Polly Jen, PharmD, and George Rusuloj, PharmD.

Disclosure Disclaimer

In accordance with the disclosure policies of UMDNJ and to conform with ACCME and FDA guidelines, individuals in a position to control the content of this education activity are required to disclose to the activity participants: 1) the existence of any relevant financial relationship with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, with the exemption of non-profit or government organizations and non-health care related companies, within the past 12 months; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device not yet approved.

Faculty Disclosure Declarations

Therewere no relevant financial relationships to disclose reported by the activity director, faculty, planning committee members, editor, content reviewers or field testers.

Off-Label Usage Disclosure

This activity does not contain information of commercial products/devices that are unlabeled for use or investigational uses of products not yet approved.

Content Disclaimer

The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of NJDHSS-Division of HIV/AIDS Services, UMDNJ, or any manufacturer of pharmaceuticals. It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk, are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating presenters.The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult the full prescribing information on any agent(s) presented in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication.

Copyright © 2010 UMDNJ-Center for Continuing and Outreach Education. All rights reserved including translation into other languages.No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from UMDNJ-Center for Continuing and Outreach Education. Please direct CME related questions to UMDNJ at 973-972-4267 or email ccoe@ca.rutgers.edu.


 

© Copyright ©2014, Rutgers, The State University of New Jersey, an equal opportunity, affirmative action institution.

Privacy Policy